Bristol Myers returns TIGIT bispecific to Agenus, frees itself from $1B+ milestones
Bristol Myers Squibb has backed out of a TIGIT partnership with Agenus, returning a bispecific that it had paid $200 million upfront to license. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
